IL-6 controls leukemic multipotent progenitor cell fate and contributes to chronic myelogenous leukemia development. - Wikidata - awgldk - TriplyDB

IL-6 controls leukemic multipotent progenitor cell fate and contributes to chronic myelogenous leukemia development.

IL-6 controls leukemic multipotent progenitor cell fate and contributes to chronic myelogenous leukemia development.

http://www.wikidata.org/entity/Q39255906

about

The NF-κB Pathway and Cancer Stem Cells Cytokine Regulation of Microenvironmental Cells in Myeloproliferative Neoplasms Stem Cell Hierarchy and Clonal Evolution in Acute Lymphoblastic Leukemia Molecular mechanisms for survival regulation of chronic myeloid leukemia stem cells Expression of the TEL-Syk fusion protein in hematopoietic stem cells leads to rapidly fatal myelofibrosis in mice Challenging the axiom: does the occurrence of oncogenic mutations truly limit cancer development with age?Aging-associated inflammation promotes selection for adaptive oncogenic events in B cell progenitors Aberrant Notch Signaling in the Bone Marrow Microenvironment of Acute Lymphoid Leukemia Suppresses Osteoblast-Mediated Support of Hematopoietic Niche Function.Combined MEK and JAK inhibition abrogates murine myeloproliferative neoplasm.p38 MAPK inhibits breast cancer metastasis through regulation of stromal expansion.Interleukin-18 produced by bone marrow-derived stromal cells supports T-cell acute leukaemia progression Ischemic stroke activates hematopoietic bone marrow stem cells IGF-IR determines the fates of BCR/ABL leukemia.JAK-STAT pathway activation in malignant and nonmalignant cells contributes to MPN pathogenesis and therapeutic response Treatment of chronic myelogenous leukemia by blocking cytokine alterations found in normal stem and progenitor cells Dissecting the role of aberrant DNA methylation in human leukaemia.Modification of Gene Expression, Proliferation, and Function of OP9 Stroma Cells by Bcr-Abl-Expressing Leukemia Cells.Altered microenvironmental regulation of leukemic and normal stem cells in chronic myelogenous leukemia Dipeptide species regulate p38MAPK-Smad3 signalling to maintain chronic myelogenous leukaemia stem cells.IL-33 signaling contributes to the pathogenesis of myeloproliferative neoplasms Regulation of stress-induced hematopoiesis Distinct roles for long-term hematopoietic stem cells and erythroid precursor cells in a murine model of Jak2V617F-mediated polycythemia vera.Context-specific roles for paracrine IL-6 in lymphomagenesis.Chemoselection of allogeneic HSC after murine neonatal transplantation without myeloablation or post-transplant immunosuppression.FoxO1-dependent induction of acute myeloid leukemia by osteoblasts in mice Senescence-associated secretory phenotype favors the emergence of cancer stem-like cells.Novel oral transforming growth factor-β signaling inhibitor EW-7197 eradicates CML-initiating cells.Regulation of c-Myc ubiquitination controls chronic myelogenous leukemia initiation and progression.Coordinate regulation of residual bone marrow function by paracrine trafficking of AML exosomes.Depletion of Jak2V617F myeloproliferative neoplasm-propagating stem cells by interferon-α in a murine model of polycythemia vera MicroRNA-146a acts as a guardian of the quality and longevity of hematopoietic stem cells in mice.Rps14 haploinsufficiency causes a block in erythroid differentiation mediated by S100A8 and S100A9 Nras(G12D/+) promotes leukemogenesis by aberrantly regulating hematopoietic stem cell functions Differential regulation of myeloid leukemias by the bone marrow microenvironment.Long-term cultured mesenchymal stem cells frequently develop genomic mutations but do not undergo malignant transformation.Expression of functional neuronal receptor latrophilin 1 in human acute myeloid leukaemia cells.The hematopoietic stem-cell niche in health and leukemia.Ponatinib overcomes FGF2-mediated resistance in CML patients without kinase domain mutations.Leukaemogenic effects of Ptpn11 activating mutations in the stem cell microenvironment.Cordycepin disrupts leukemia association with mesenchymal stromal cells and eliminates leukemia stem cell activity.

P2860

Q26750605-FD556CF9-E614-4F01-8A1C-534FC4D48EBA Q26778929-D19970C2-40AB-411B-931A-D528CD008393 Q26799954-25747B73-5BD5-4C47-BA67-EAB1D44756C9 Q26828528-08B6C0E9-0E80-4BBE-9278-2A7F458730ED Q27303848-D3B17DBD-34DB-4AFF-93E3-48424CE54C54 Q28383732-49C15E32-7AAF-4A46-9D62-84A372D3C9F7 Q28395194-41FAB054-2B93-4E74-8700-DBAAAECD7FE9 Q33429438-2810CE92-3318-4305-9F06-96FD5C96B9D8 Q33685977-739847CE-D4B4-430B-AE64-317E1E4527FD Q34356907-FE5EEF6D-9C3E-4C2E-BA84-D9DD5FE77930 Q34372296-356E1ECB-AD36-4E56-A79B-E1C094093F6D Q35033609-8110E13D-F1E8-4FFB-A6E8-7C71FBD75AAA Q35061363-7303397D-DECA-4CFF-AAA1-06B3D1CC0BBC Q35163764-7CBB4CCD-EA40-4207-8E3D-46AA58428CA2 Q35627994-0535C108-B941-48EA-B44D-073583E5DD72 Q35645500-7CDAE631-E7F3-4377-85F7-29209A33CC2E Q35719210-27157442-2B4D-4DE6-BC3A-7D4BB86180EF Q35903505-A62918B8-5CB5-4AF2-AF97-73EE4DAF34D5 Q36030083-73D8C440-DD5A-40E7-A811-77A9EA21D618 Q36040193-36B24F68-8666-4D3E-B9A6-07001DA3A988 Q36069153-3CE87181-0B28-4C0F-BF87-F8D83865B137 Q36079782-2C79298D-C4B7-4361-A345-F4F1FE998746 Q36162671-0F1B76FB-1E96-48B5-B3DB-9F81AF6543B1 Q36401055-2E0E2C23-33E0-4270-883F-F2B2F1627533 Q36404458-108EAD29-E741-4C17-9EAC-DB384CEFEFD7 Q36525196-D4DCA033-EE47-4A97-8B57-4B24B6999153 Q36622106-959CC17E-917B-4072-9A1E-0E23DF5EE5A3 Q36720075-1ECADD5C-DE8C-47A4-A775-C580BA2E5754 Q36807754-5D5F2A4A-EB32-47EE-A56C-9970DCE2D100 Q36814639-F770C7D8-9B4D-4C27-BC6E-19E2D472A7DA Q36864863-D7F7D9E7-983C-4738-9FD2-20A8935BD9DA Q36909178-D4163B54-7D83-4656-B303-85570DD1491E Q36962687-2DAE5B8B-EEA7-4E5B-9EBE-030EEF880EF6 Q37308308-A30CEEA6-28AB-46A7-B1A6-F6A34ED04107 Q37424076-A1EDE43A-3EB3-483F-9A02-865F8F4B1B36 Q37564487-441CEADA-CAA8-4AE2-A1A9-3B8F58C9C31A Q37610816-103F8D6D-C18E-431E-8E56-721F3B1E576B Q37623532-3BA64D47-517E-431E-BCF3-086046241C63 Q37653117-3081393A-89BC-47EC-B416-8FA40575F70D Q37683837-FC331920-9151-4C85-9B6B-DEEAF6B6C42F

P2860

IL-6 controls leukemic multipotent progenitor cell fate and contributes to chronic myelogenous leukemia development.

http://www.wikidata.org/entity/Q39255906

description

2011 nî lūn-bûn

@nan

2011年の論文

@ja

2011年学术文章

@wuu

2011年学术文章

@zh-cn

2011年学术文章

@zh-hans

2011年学术文章

@zh-my

2011年学术文章

@zh-sg

2011年學術文章

@yue

2011年學術文章

@zh

2011年學術文章

@zh-hant

name

IL-6 controls leukemic multipo ...... logenous leukemia development.

@en

IL-6 controls leukemic multipo ...... logenous leukemia development.

@nl

type

label

IL-6 controls leukemic multipo ...... logenous leukemia development.

@en

IL-6 controls leukemic multipo ...... logenous leukemia development.

@nl

prefLabel

IL-6 controls leukemic multipo ...... logenous leukemia development.

@en

IL-6 controls leukemic multipo ...... logenous leukemia development.

@nl

P1433

Q39255906-4AD95DA9-3C92-4CA7-BF7F-0EA6AE28F4FD

P1476

Q39255906-B3DA52B5-47FF-478A-BA62-D5CACADEB4AF

P2093

Q39255906-088F0CBD-89E9-449D-997F-8A624ABFB8EE

Q39255906-3B910860-161E-4A60-9CDE-2378F0A0C7AA

Q39255906-64F86F2A-42B9-443F-BDEE-513731213559

Q39255906-BA722B9E-99B6-4326-BAC0-33F89343F7A6

Q39255906-BB171334-6FD5-40DB-96C9-BD0081333231

Q39255906-C291CCDF-1EED-4CCC-8984-3ACDB038D5BB

Q39255906-E4F71E42-40E1-48B3-813A-A6C224E0305A

Q39255906-ED39EE6B-6637-470E-B459-E220940620A7

Q39255906-ED49F8AA-F147-4310-B667-3675C9A8B833

P2860

Q39255906-03C82D93-F95F-49AE-ABF3-D49999DB6350

Q39255906-082AB6B3-6A7A-4FDF-805E-7BA5005507AA

Q39255906-0C8139D4-B0D5-4FB3-9B87-2E4BAAFC6584

Q39255906-0D8355A5-845F-42F3-A757-36554E6A2095

Q39255906-10545AD0-1BB0-4AA5-AB0C-ACE58A1BD93B

Q39255906-24A02D13-BC0F-44BD-A29A-5536A6D33B07

Q39255906-2B84286F-B4A5-4C37-9ACD-A48859726EE7

Q39255906-2C9990FA-2859-4DB4-85AE-C8BD755F8DA9

Q39255906-41F47EE2-74CA-4830-BC41-A8AC7916B60B

Q39255906-443AC6E8-9558-44FC-8636-4DDDC5D02E30

P304

Q39255906-1903CCF2-B8A9-41BE-AED9-13469C68F658

P31

Q39255906-4C234D21-896B-4923-B867-706A4D8A7ADC

P356

Q39255906-172411AD-11D4-4405-A1C2-2B48FD0C683A

P433

Q39255906-E37CCD11-5F77-4FB3-9021-158C5D0B2F96

P478

Q39255906-D3A757CC-2A46-4B94-8AE7-DB2C1C20F9B0

P577

Q39255906-B89B0A73-9C1C-4365-8D94-98AD1498B07A

P5875

Q39255906-7CB8AD41-A204-4518-BF85-A99B5665D540

P698

Q39255906-6C7BE049-6BC5-4A00-AE26-A2D136BB2002

P921

Q39255906-16414776-9404-4DCC-8DB2-B7A874DD430C

P932

Q39255906-985C1591-C4E4-47D6-96C0-D78FA155C28B

P356

J.CCR.2011.10.012

P1433

P1476

IL-6 controls leukemic multipo ...... logenous leukemia development.

@en

P2093

Alain Mir

http://www.w3.org/2001/XMLSchema#string

Damien Reynaud

http://www.w3.org/2001/XMLSchema#string

Emmanuelle Passegué

http://www.w3.org/2001/XMLSchema#string

Eric Pietras

http://www.w3.org/2001/XMLSchema#string

Jerald P Radich

http://www.w3.org/2001/XMLSchema#string

Keegan Barry-Holson

http://www.w3.org/2001/XMLSchema#string

Marion Jeanne

http://www.w3.org/2001/XMLSchema#string

Mikhail Binnewies

http://www.w3.org/2001/XMLSchema#string

Olga Sala-Torra

http://www.w3.org/2001/XMLSchema#string

P2860

An epigenetic switch involving NF-kappaB, Lin28, Let-7 MicroRNA, and IL6 links inflammation to cell transformation

Modeling the initiation and progression of human acute leukemia in mice

BCL-6 negatively regulates macrophage proliferation by suppressing autocrine IL-6 production

Isolation of a highly quiescent subpopulation of primitive leukemic cells in chronic myeloid leukemia.

BCR-ABL enhances differentiation of long-term repopulating hematopoietic stem cells

Effective targeting of quiescent chronic myelogenous leukemia stem cells by histone deacetylase inhibitors in combination with imatinib mesylate.

Chronic myeloid leukemia: mechanisms of blastic transformation

Gene expression changes associated with progression and response in chronic myeloid leukemia.

A novel tumour-suppressor function for the Notch pathway in myeloid leukaemia.

Targeting multiple kinase pathways in leukemic progenitors and stem cells is essential for improved treatment of Ph+ leukemia in mice.

P304

661-673

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.CCR.2011.10.012

http://www.w3.org/2001/XMLSchema#string

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

20

http://www.w3.org/2001/XMLSchema#string

P577

2011-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51806595

http://www.w3.org/2001/XMLSchema#string

P698

22094259

http://www.w3.org/2001/XMLSchema#string

P921

P932

3220886

http://www.w3.org/2001/XMLSchema#string